title: SN-38:β-cyclodextrin inclusion complex for in situ solidifying injectable polymer implants.
abstract: One of the most useful techniques to treat cancer is chemotherapy. However, anticancer drugs, such as SN-38, have limited solubility with strong side effects. This work aims to use SN-38:β-cyclodextrin (β-CD) inclusion complex for an injectable polymeric in situ forming implant containing poly(ethylene glycol) (PEG), poly(ε-caprolactone), and poly(D, L-lactide). It was found that implant formation and SN-38 encapsulation efficiency directly depended on weight ratio of SN-38 and β-CD. At the ratio of SN-38:β-CD of 1:7, the implant could not be formed perfectly and had lower encapsulation efficiency. Reduction of the amount of β-CD to the ratio of 1:3 showed the higher encapsulation efficiency at 89.7 %. SN-38 release rate was also found to depend on β-CD content and the implant weight. In addition, their active form was protected when encapsulated inside implants.
authors.affiliation: Biomedical Engineering Department, Mahidol University, Nakorn Pathom, CO 73170, Thailand
authors.forename: Chawan
authors.initials: C
authors.lastname: Manaspon
authors.forename: Pinunta
authors.initials: P
authors.lastname: Nittayacharn
authors.forename: Ketpat
authors.initials: K
authors.lastname: Vejjasilpa
authors.forename: Chayut
authors.initials: C
authors.lastname: Fongsuk
authors.forename: Norased
authors.initials: N
authors.lastname: Nasongkla
mesh_terms: D000972:Antineoplastic Agents, Phytogenic / Q000737:chemistry*; D002166:Camptothecin / Q000031:analogs & derivatives* / Q000737:chemistry; D004343:Drug Implants; D000077146:Irinotecan; D011108:Polymers / Q000737:chemistry*; D047392:beta-Cyclodextrins / Q000737:chemistry*
chemical_list: D000972:Antineoplastic Agents, Phytogenic; D004343:Drug Implants; D011108:Polymers; D047392:beta-Cyclodextrins; D000077146:Irinotecan; C031215:betadex; D002166:Camptothecin